Skip to main content

Engaging Patients in Decision Helps Reduce Antibiotic Use


July 30, 2012 — Training physicians to engage patients in decision-making can reduce the prescription of unnecessary antibiotics for acute respiratory infections, according to a randomized trial of 359 patients published in the Canadian Medical Association Journal.
In the cluster randomized trial, the use of antibiotics for acute respiratory infection was reduced by 25% among patients of Canadian physicians from 5 family practices who were trained in physician–patient shared decision-making compared with use among patients of physicians who provided "usual care" (27.2% vs 52.2%; adjusted relative risk, 0.48; 95% confidence interval, 0.34 - 0.68).
The reduction in antibiotic use had no significant effect on patient outcomes from respiratory infection 2 weeks after patients consulted with their physicians about symptoms of acute respiratory infection, according to lead author France Légaré, MD, PhD, from the Research Centre of the Centre Hospitalier Universitaire de Québec and the Department of Family Medicine and Emergency Medicine, Université Laval, Québec, Canada, and colleagues.
"Our data suggest that it is possible to train physicians to engage patients actively in decision-making. In the context of acute respiratory infections, this appears to reduce the use of a treatment option (i.e., antibiotics) not clearly associated with benefits for all patients," the authors write.
In the multicenter, parallel cluster randomized trial, the researchers compared use of antibiotics for acute respiratory infection among patients of 77 physicians who participated in the physician–patient shared decision-making training program with prescriptions for antibiotics among 72 physicians who provided usual care.
As well as reducing use of antibiotics for acute respiratory infections, patients of physicians who took the training program took a more active role in decision-making about their treatment compared with patients of physicians in the control group (P < .001). Active patient decision-making was assessed by a questionnaire after the physician–patient consultation and the Control Preference Scale, which assessed patient perceptions that shared decision-making had occurred.
The shared decision-making training program, known as DECISION+2, consisted of a 2-hour online tutorial followed by a 2-hour interactive seminar on shared physician–patient decision-making. The program included information about the scientific evidence for use of antibiotics in acute respiratory infection as well as training in communication with patients about the risks and benefits of antibiotic use.
In the training program, physicians were also educated about ways to promote active patient participation in the decision of whether or not to use antibiotics. These techniques included asking patients about their preferences and values and verifying patient comfort with the final decision about use of antibiotics.
The authors noted that training programs in shared patient–clinician decision-making might be useful in other settings such as emergency departments or to train nurses to help patients make informed decisions based on their values before visiting a physician or emergency department.
The study was funded by a grant from the Conseil du médicament du Québec/Fonds de la recherche en santé du Québec. The authors have disclosed no relevant financial relationships.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more